InterMune reiterated at market perform by JMP

JMP Securities analyst Adam Cutler reiterated InterMune, Inc. at market perform following the company's reported second-quarter loss per share of $1.33. Not including a one-time $30 million legal settlement charge, loss per share was $0.42, compared to JMP's estimate of a $0.47 loss per share and the Street's estimate of a $0.41 loss per share. Revenue, made up entirely of Actimmune sales of $24.1 million, beat the analyst's estimate of $22.0 million and the Street's estimate of $24.0 million. Shares of the Brisbane, Calif.-based biotechnology company were up 55 cents, or 3.50%, at $16.26 on volume of 474,905 shares versus the three-month running average of 372,597 shares. (Nasdaq: ITMN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.